Sign in Subscribe
Cancer

Long-term Outcomes of Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency

Strategic Insights

— 1 min read

New research on gene therapy for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID) has shown promising long-term outcomes, but also highlights potential risks of genotoxicity with certain viral vectors. A cohort of 10 patients, aged 3 months to 15 years, underwent gene therapy in a phase 2 clinical trial between 2009 and 2012. Funders for this research included the US Food and Drug Administration Office of Orphan Products Development, the National Institutes of Health, and the California Institute for Regenerative Medicine.

Key Takeaways:

  • Nine out of 10 patients achieved sufficient immune reconstitution to protect against serious infections without needing to resume enzyme replacement therapy (ERT) or proceed to secondary allogeneic hematopoietic stem cell transplantation (HSCT).
  • Four of 9 evaluable patients with the highest gene marking and B-cell numbers remained off immunoglobulin replacement therapy and responded to vaccines.
  • Outcomes were generally better in younger patients and those receiving higher doses of gene-marked CD34(+) cells.
  • No patient experienced a leukoproliferative event after gene therapy, but some had persisting clones with vector integrations adjacent to proto-oncogenes.
  • Gene therapy was found to be effective in treating ADA-SCID, but the study highlights the need for caution in the use of certain viral vectors due to potential genotoxicity risks.

Statistics:

  • 10 patients underwent gene therapy in the phase 2 clinical trial.
  • 9 out of 10 patients achieved sufficient immune reconstitution.
  • 4 out of 9 evaluable patients remained off immunoglobulin replacement therapy.
  • Patients received busulfan reduced-intensity conditioning and were infused with gene-marked CD34+ cells.
  • Follow-up performed over 8 to 11 years.

Sources:

  • University of California Los Angeles (UCLA)
  • Blood
  • American Society of Hematology
  • NewsRx
  • Long-term Outcomes After Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (Blood, 2021;138(15):1304-1316)

Read more